Literature DB >> 7505480

Prospect for an additional laboratory criterion for rheumatoid arthritis.

R von Essen1, P Kurki, H Isomäki, S Okubo, H Kautiainen, K Aho.   

Abstract

The aim of the study was to establish the benefit of an additional hypothetical laboratory criterion for rheumatoid arthritis (RA), comprising positivity for antikeratin antibody (AKA) and/or antiperinuclear factor (APF). The tests were applied to a series of 308 hospital patients with various recent-onset inflammatory joint diseases who were followed for 3 years. The performance of APF and AKA was compared with rheumatoid factor (RF). The most sensitive (.72) but the least specific (.86) test for RA was the latex test. The most specific (.96) but the least sensitive (.33) test was AKA. Waaler-Rose and APF were intermediate. AKA and/or APF positive patients had significantly more erosions than patients negative for these autoantibodies. Despite the impressive performance characteristics of APF and AKA, the actual classification impact achieved, as compared to using RF as the sole laboratory criterion, turned out to be moderate. This is because the criteria proved to be interrelated. Unlike RF, AKA and APF are not suited to the general laboratory, at least not in their present form. Moreover they so far lack the broad data base of RF.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7505480     DOI: 10.3109/03009749309095137

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  8 in total

1.  The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies.

Authors:  M Sebbag; M Simon; C Vincent; C Masson-Bessière; E Girbal; J J Durieux; G Serre
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

2.  Anti-perinuclear factor compared with the so called "antikeratin" antibodies and antibodies to human epidermis filaggrin, in the diagnosis of arthritides.

Authors:  C Vincent; F de Keyser; C Masson-Bessière; M Sebbag; E M Veys; G Serre
Journal:  Ann Rheum Dis       Date:  1999-01       Impact factor: 19.103

3.  Performance of two ELISAs for antifilaggrin autoantibodies, using either affinity purified or deiminated recombinant human filaggrin, in the diagnosis of rheumatoid arthritis.

Authors:  L Nogueira; M Sebbag; C Vincent; M Arnaud; B Fournié; A Cantagrel; M Jolivet; G Serre
Journal:  Ann Rheum Dis       Date:  2001-09       Impact factor: 19.103

4.  Antikeratin antibodies (AKA) negativity in primary biliary cirrhosis (PBC): confirmation of their specificity in the diagnosis of rheumatoid arthritis (RA)

Authors:  M Fusconi; C Berti Ceroni; G Monti; F Cassani; C A Busachi; R Corinaldesi; F Bianchi
Journal:  Clin Rheumatol       Date:  1996-11       Impact factor: 2.980

5.  Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage.

Authors:  O Meyer; C Labarre; M Dougados; Ph Goupille; A Cantagrel; A Dubois; P Nicaise-Roland; J Sibilia; B Combe
Journal:  Ann Rheum Dis       Date:  2003-02       Impact factor: 19.103

6.  Anti-perinuclear Factor as Diagnostic Marker in Rheumatoid Arthritis.

Authors:  Zeinab Abedian; Masoud Sagafi; Saeid Abedian Kenari; Farshideh Abedian
Journal:  J Clin Diagn Res       Date:  2015-09-01

7.  Prevalence of autoantibodies to cyclic citrullinated peptide in patients with rheumatic diseases other than rheumatoid arthritis: a French multicenter study.

Authors:  Nicole Fabien; Nils-Olivier Olsson; Joëlle Goetz; Catherine Johanet; Andrée Escande; Nathalie Bardin; Marielle Sanmarco; Chantal Andre; Alain Chevailler; René-Louis Humbel; Pascale Chretien; Jean-claude Monier; Françoise Fortenfant; Françoise Oksman; Marie-France Taillefer; Jean Sibilia
Journal:  Clin Rev Allergy Immunol       Date:  2008-02       Impact factor: 8.667

8.  A new classification of HLA-DRB1 alleles differentiates predisposing and protective alleles for autoantibody production in rheumatoid arthritis.

Authors:  Pierre-Antoine Gourraud; Philippe Dieudé; Jean-Frédéric Boyer; Leonor Nogueira; Anne Cambon-Thomsen; Bernard Mazières; François Cornélis; Guy Serre; Alain Cantagrel; Arnaud Constantin
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.